

DORSET MEDICINES ADVISORY GROUP

COMMISSIONING STATEMENT ON USE OF LIRAGLUTIDE (SAXENDA®) IN WEIGHT MANAGEMENT

SUMMARY	
NHS Dorset Clinical Commissioning Group supports the use of liraglutide (Saxenda®) for weight management within NICE TA664 .	
BACKGROUND	<p>Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor antagonist.</p> <p>Liraglutide (Saxenda®) received a European marketing authorisation in March 2015 and was launched in the UK in January 2017.</p> <p>Liraglutide as Saxenda® is a different licensed product to liraglutide as Victoza® and the doses of Saxenda® used for weight management are different to that used in managing type 2 diabetes with Victoza®.</p>
RELEVANT NICE GUIDANCE	<p>NICE TA 664 states:</p> <p>Liraglutide is recommended as an option for managing overweight and obesity alongside a reduced-calorie diet and increased physical activity in adults, only if:</p> <ul style="list-style-type: none"> • they have a body mass index (BMI) of at least 35 kg/m² (or at least 32.5 kg/m² for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population) and • they have non-diabetic hyperglycaemia (defined as a haemoglobin A1c level of 42 mmol/mol to 47 mmol/mol [6.0% to 6.4%] or a fasting plasma glucose level of 5.5 mmol/litre to 6.9 mmol/litre) and • they have a high risk of cardiovascular disease based on risk factors such as hypertension and dyslipidaemia and • it is prescribed in secondary care by a specialist multidisciplinary tier 3 weight management service and • the company provides it according to the commercial arrangement.
FORMULARY STATUS	Red (for use within the tier 3 weight management service only)
PBR STATUS	In tariff
COMMISSIONING IMPLICATIONS	The tier 3 weight management service for Dorset is provided by Spire Southampton. Clinicians within that service will provide Saxenda®. There will be no requirement for GPs to prescribe.
RELEVANT CLINICAL WORKING GROUP	Discussed with the Diabetes & Endocrinology Working Group of Dorset Medicines Advisory Group (DMAG)

PATIENT PATHWAY IMPLICATIONS	Liraglutide (Saxenda®) for weight management should only be used within Dorset as part of a tier 3 weight management service provided at the Spire Hospital in Southampton, and only for those patients meeting the criteria defined by the NICE guidance.
SUMMARY OF EVIDENCE TO SUPPORT FORMULARY STATUS	<p>Management for overweight and obesity in adults includes lifestyle measures alone, lifestyle measures with orlistat, or bariatric (weight loss) surgery.</p> <p>The company's evidence submission focuses on people with a BMI of at least 35 kg/m² with non-diabetic hyperglycaemia and a high risk of cardiovascular disease, because this group of people was at high risk of experiencing the adverse consequences of obesity. They were also likely to gain most from liraglutide. The clinical evidence shows that people lose more weight with liraglutide plus lifestyle measures than with lifestyle measures alone. Liraglutide has also been shown to delay the development of type 2 diabetes and cardiovascular disease.</p> <p>People from some minority ethnic groups are at an equivalent risk of the consequences of obesity at a lower BMI than the white population. NICE's guideline on BMI recommends using lower BMI thresholds for people from south Asian, Chinese, black African and African-Caribbean populations when identifying the risk of developing type 2 diabetes and providing interventions to prevent it. Therefore, a similar adjustment in the BMI threshold is appropriate when considering liraglutide for people from minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.</p> <p>For people with a high BMI, non-diabetic hyperglycaemia and a high risk of cardiovascular disease the cost-effectiveness estimates are within what is normally considered a cost-effective use of NHS resources. For these people, liraglutide is recommended.</p>
ASSESSMENT OF COST IMPLICATIONS	<p>Saxenda costs £196.20 for 5 pre-filled disposable injections (30 days' supply) at the maintenance dose of 3.0 mg daily. (BNF Online, Sept 20).</p> <p>A commercial agreement has been agreed, in confidence.</p>
REFERENCES	Liraglutide for managing overweight and obesity (NICE TA 664)
DATE	December 2020
REVIEW DATE	November 2022
CONTACT FOR THIS POLICY	medicine.question@dorsetccg.nhs.uk